$NVDA — AVOID 📊 | 6 MONTHS THESIS

$NVDA — AVOID 📊 | 6 MONTHS THESIS 🧭 Conviction: HIGH 🎯 FQ1 FY2027 (ends Apr) | reported May 20 | Rev $81.6B | EPS $1.87 vs $1.77 🟢 | Margin 69.0% 💡 Consensus assumes sustained hypergrowth and margin expansion, but the reverse DCF implies -2.7% FCF growth is needed to justify the price. Any deceleration in AI capex or margin compression would trigger sharp multiple contraction toward peer median 18.7x. 🏢 Business Quality: 10/10 📊 Valuation: rich — trailing P/E 25.7x vs peer band 7.4x-18.7x-46.2x, 113th percentile historically; DCF implies negligible growth; FCF yield ~1.1% is low for... 🔮 Catalyst: Next quarterly earnings or AI sector sentiment shift ⚖️ Avoid NVDA at $192.53: exceptional business but rich valuation with 0.3:1 objective reward/risk fails entry criteria—await a better price near $120-150 where base case upside exceeds 2:1.

🧭 Conviction: HIGH